Press release
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graves Ophthalmopathy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Graves Ophthalmopathy Research. Learn more about our innovative pipeline today! @ Graves Ophthalmopathy Pipeline Outlook- https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Graves Ophthalmopathy Pipeline Report
• In November 2024:- Viridian Therapeutics- This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.
• In November 2024:- Amgen- The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a ≥ 2-mm reduction from Baseline in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye) at Week 24. The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
• In November 2024:- ACELYRIN Inc.- A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects with Thyroid Eye Disease (TED). Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
• The leading Graves Ophthalmopathy Companies such as Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others
• Promising Graves Ophthalmopathy therapies such as Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
Stay informed about the cutting-edge advancements in Graves Ophthalmopathy treatments. Download for updates and be a part of the revolution in care @ Graves Ophthalmopathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Graves Ophthalmopathy Emerging Drugs
• VRDN-001: Viridian
Viridian's lead product candidate, VRDN-001, is a potential best-in-class, IV monoclonal antibody targeting IGF-1R. VRDN-001 acts as a full antagonist of IGF-1R, and based on clinical data to date, has demonstrated robust clinical activity and was generally well-tolerated at Week 6 compared with the currently approved anti-IGF-1R antibody. Currently, the drug is in Phase III stage of its clinical trial for the treatment Graves' Ophthalmopathy.
• TOUR006: Tourmaline Bio
TOUR006 is a long-acting, fully human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. TOUR006 has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing TOUR006 in thyroid eye disease and atherosclerotic cardiovascular disease as its first two indications, with additional diseases under consideration. Currently, the drug is in Phase II Stage of its clinical trial for the treatment of Graves' Ophthalmopathy.
Learn more about Graves Ophthalmopathy Drugs opportunities in our groundbreaking Graves Ophthalmopathy Research and development projects @ Graves Ophthalmopathy Unmet Needs- https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Graves Ophthalmopathy Companies
Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others.
Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Graves Ophthalmopathy Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Graves Ophthalmopathy treatment by visiting our website. Stay informed about how we're transforming the future of disease @ MyeloGraves Ophthalmopathy fibrosis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Graves Ophthalmopathy Pipeline Report
• Coverage- Global
• Graves Ophthalmopathy Companies- Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others
• Graves Ophthalmopathy Therapies- Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
• Graves Ophthalmopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelo Graves Ophthalmopathy fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Graves Ophthalmopathy Pipeline on our website @ Graves Ophthalmopathy Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Graves Ophthalmopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Graves Ophthalmopathy - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. VRDN-001: Viridian
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. TOUR006: Tourmaline Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Graves Ophthalmopathy Key Companies
21. Graves Ophthalmopathy Key Products
22. Graves Ophthalmopathy- Unmet Needs
23. Graves Ophthalmopathy- Market Drivers and Barriers
24. Graves Ophthalmopathy- Future Perspectives and Conclusion
25. Graves Ophthalmopathy Analyst Views
26. Graves Ophthalmopathy Key Companies
27. Appendix
List of Highly Demanded Research Reports in 2024
cxcr inhibitors market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
fertility monitoring devices market: https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
ornithine transcarbamylase deficiency market: https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
orthopedic power devices market: https://www.delveinsight.com/report-store/orthopedic-power-devices-market
otitis media market: https://www.delveinsight.com/report-store/otitis-media-market
persistent depressive disorder market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
smoking cessation market: https://www.delveinsight.com/report-store/smoking-cessation-market
surgical sealant market: https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
urothelial carcinoma market: https://www.delveinsight.com/report-store/urothelial-carcinoma-market
vascular grafts market: https://www.delveinsight.com/report-store/vascular-grafts-market
vital sign monitors devices market: https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
aplastic anemia market: https://www.delveinsight.com/report-store/aplastic-anemia-market
cart pipeline: https://www.delveinsight.com/report-store/car-t-pipeline-insight
celiac disease market: https://www.delveinsight.com/report-store/celiac-disease-cd-market
coronary stents market: https://www.delveinsight.com/report-store/coronary-stents-market-market
diabetic gastroparesis market: https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
elastomeric pump market: https://www.delveinsight.com/report-store/elastomeric-pump-market
friedreich's ataxia market: https://www.delveinsight.com/report-store/friedreichs-ataxia-market
hay fever conjunctivitis market: https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
hip replacement devices market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
joint reconstruction devices market: https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
periodontal disease market: https://www.delveinsight.com/report-store/periodontal-disease-market
psoriasis vulgaris market: https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
ranibizumab biosimilars market: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
short bowel syndrome drug market: https://www.delveinsight.com/report-store/short-bowel-syndrome-market
short bowel syndrome market: https://www.delveinsight.com/report-store/short-bowel-syndrome-market
thrombectomy devices market: https://www.delveinsight.com/report-store/thrombectomy-devices-market
type 1 diabetes market: https://www.delveinsight.com/report-store/type-1-diabetes-market
adhd market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
attention deficit hyperactivity disorder market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
avascular necrosis market: https://www.delveinsight.com/report-store/avascular-necrosis-market
biopsy devices market: https://www.delveinsight.com/report-store/biopsy-devices-market
embolotherapy market: https://www.delveinsight.com/report-store/embolotherapy-market
hydrocephalus treatment market: https://www.delveinsight.com/report-store/hydrocephalus-treatment-market
liquid biospy for cancer diagnostics market: https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
skin grafting devices market: https://www.delveinsight.com/report-store/skin-grafting-devices-market
testicular neoplasm market: https://www.delveinsight.com/report-store/testicular-neoplasm-market
uk healthcare report: https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market: https://www.delveinsight.com/report-store/vascular-access-device-market
brucellosis market: https://www.delveinsight.com/report-store/brucellosis-market
catheter stabilization devices market: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
dyspepsia market: https://www.delveinsight.com/report-store/functional-dyspepsia-market-share
heart pump devices market: https://www.delveinsight.com/report-store/heart-pump-device-market
phototherapies for psoriasis market: https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
radial artery compression device market: https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
sarcopenia market: https://www.delveinsight.com/report-store/sarcopenia-market
shingles market: https://www.delveinsight.com/report-store/shingles-market
surgical site infections market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
venous ulcer market: https://www.delveinsight.com/report-store/venous-leg-ulcer-market
viscosupplementation devices market: https://www.delveinsight.com/report-store/viscosupplementation-devices-market
artificial disc market: https://www.delveinsight.com/report-store/artificial-disc-market
healthcare consulting solutions: https://www.delveinsight.com/consulting
meningococcal meningitis market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
moderate to severe plaque psoriasis market: https://www.delveinsight.com/blog/us-psoriasis-treatment
pertussis market: https://www.delveinsight.com/report-store/pertussis-market
spinal trauma devices market: https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
surgical energy instruments market: https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
temporomandibular disorders market: https://www.delveinsight.com/report-store/temporomandibular-disorders-market
transcatheter heart valve replacement devices market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
urinary catheters market: https://www.delveinsight.com/report-store/urinary-catheters-market
attention deficit hyperactivity disorder adhd market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
coronary angioplasty market: https://www.delveinsight.com/report-store/coronary-stents-market-market
nonalcoholic steatohepatitis market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
orthopedic splints device market: https://www.delveinsight.com/report-store/orthopedic-splints-market
perennial allergic rhinitis market: https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
pipeline assessment services: https://www.delveinsight.com/consulting/pipeline-assessment-services
schistosomiasis market: https://www.delveinsight.com/report-store/schistosomiasis-market
venous thromboembolism market: https://www.delveinsight.com/report-store/venous-thromboembolism-market
bacterial meningitis market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
nk cell therapy market: https://www.delveinsight.com/report-store/nk-cell-therapy-market
overactive bladder syndrome market: https://www.delveinsight.com/report-store/overactive-bladder-market
peripheral nerve injuries market: https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market
tendonitis market: https://www.delveinsight.com/report-store/tendonitis-market
endoscopic ultrasound market: https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated) here
News-ID: 3765805 • Views: …
More Releases from DelveInsight Business Research LLP

Atopic Dermatitis Clinical, Companies, Therapeutic Assessment, Therapies, Treatm …
Atopic Dermatitis Pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analyzes DelveInsight.
Atopic Dermatitis Overview:
Atopic Dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition and the most prevalent form of skin inflammation. While it often begins in early childhood, it can occur at any age and may be recurrent or persist throughout life. The term "dermatitis" comes from "derm" meaning skin and…

Electrical Stimulation Devices Market Poised for Steady Growth, Fueled by Innova …
The global functional electrical stimulation (FES) devices market is projected to grow at a CAGR of 8.2% from 2024 to 2030. Growth is mainly driven by the increasing prevalence of musculoskeletal disorders worldwide, along with the growing emphasis on pain management therapies and continuous technological advancements in product development, which are expected to further boost the market in the coming years.
DelveInsight's Electrical Stimulation Devices Market Insights report provides the current…

Brain Monitoring Devices Market Poised for Steady Growth, Fueled by Innovation a …
The brain monitoring devices market, valued at USD 5.89 billion in 2023, is projected to grow at a CAGR of 7.27% from 2024 to 2030, reaching USD 9.13 billion by 2030. Growth is driven by the rising prevalence of neurological disorders such as multiple sclerosis, epilepsy, and dementia, along with increasing awareness and ongoing product development activities, all contributing to the market's expansion during the forecast period.
DelveInsight's Brain Monitoring Devices…

Sleep Apnea Devices Market Poised for Steady Growth, Fueled by Innovation and Ri …
The global sleep apnea devices market, valued at USD 7.53 billion in 2023, is projected to grow at a CAGR of 6.26% from 2024 to 2030, reaching USD 10.82 billion by 2030. Growth is driven by the rising prevalence of sleep apnea, increasing obesity rates, and greater adoption of advanced technologies. Additional factors such as heightened awareness, a growing elderly population, and a surge in product launches and approvals are…
More Releases for Graves
Search for graves and burials in Minsk
If you are looking for information about the location of the grave in Minsk or other regions of Belarus, the company https://verimby.com +375293887408 (Viber); +375447498518 (WhatsApp) offers professional assistance in this important matter. We specialize in finding burial sites, providing detailed data and providing support in restoring lost ties with the past, creating a family tree, even if you are in another country.
Why can the search for graves in Belarus…
Graves' Disease Treatment Market Size, Drugs, Companies 2034 | DelveInsight
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and…
Japan Graves' disease Market Size & Growth Analysis Report, 2019-2025
Japan Graves' disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country's population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave's disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in…
Global Graves Disease Market Status and Outlook (2020-2025)
Global Info Research offers a latest published report on Graves Disease Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Graves Disease Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/515950/graves-disease
Market…
US Graves' disease Market Growth, Share, Trends & Forecast to 2025
US Graves' disease market is growing at a CAGR of around 4.0% during the forecast period. The US Grave's disease market is showing significant growth due to funding for autoimmune disease researches, and the increasing prevalence of hyperthyroidism in the region. In addition, significant rise in the prevalence of autoimmune disease is also expected to propel the growth of the US Graves' disease market. According to the American Autoimmune Related…
Graves disease Market: Positive long-term growth outlook 2017 - 2025
Graves’ disease is an autoimmune disorder that stimulates the thyroid gland to release excessive thyroid hormone, leading to hyperthyroidism. It is termed as Basedow’s disease in continental Europe and Graves’ disease in the U.S.
In this disease, body’s immune system produces antibodies that help the thyroid gland to grow which in turn synthesizes abnormal levels of thyroid hormones causing hyperthyroidism. Graves’ disease is the most predominant cause of hyperthyroidism in the…